t’s a holiday week. Things are slow. But we’re still keeping tabs on all things pharma and biotech. Here’s what we’re looking out for this week:

Bad news

If the goal is to bury bad news, this week is the time to do it. Whether it’s a bankruptcy, layoffs, or a decision to give up on an experimental drug, companies have plenty of incentive to get that press release out of the way while hardly anyone’s paying attention. (Don’t worry. We’ll be watching.)

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy